JP2021533779A5 - - Google Patents
Info
- Publication number
- JP2021533779A5 JP2021533779A5 JP2021507761A JP2021507761A JP2021533779A5 JP 2021533779 A5 JP2021533779 A5 JP 2021533779A5 JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021507761 A JP2021507761 A JP 2021507761A JP 2021533779 A5 JP2021533779 A5 JP 2021533779A5
- Authority
- JP
- Japan
- Prior art keywords
- polypeptide
- linker
- antigen
- optionally
- seq
- Prior art date
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862765095P | 2018-08-16 | 2018-08-16 | |
| US62/765,095 | 2018-08-16 | ||
| PCT/US2019/046705 WO2020037150A2 (en) | 2018-08-16 | 2019-08-15 | Engineered bispecific proteins |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021533779A JP2021533779A (ja) | 2021-12-09 |
| JP2021533779A5 true JP2021533779A5 (https=) | 2022-08-22 |
| JPWO2020037150A5 JPWO2020037150A5 (https=) | 2022-08-22 |
| JP7397063B2 JP7397063B2 (ja) | 2023-12-12 |
Family
ID=69525976
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021507761A Active JP7397063B2 (ja) | 2018-08-16 | 2019-08-15 | 操作された二重特異性タンパク質 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20220017634A1 (https=) |
| EP (1) | EP3850007A4 (https=) |
| JP (1) | JP7397063B2 (https=) |
| KR (1) | KR20210064199A (https=) |
| CN (1) | CN112839955A (https=) |
| AU (1) | AU2019320803A1 (https=) |
| BR (1) | BR112021002730A2 (https=) |
| CA (1) | CA3109763A1 (https=) |
| EA (1) | EA202190542A1 (https=) |
| IL (1) | IL280882A (https=) |
| MA (1) | MA53616A (https=) |
| MX (1) | MX2021001711A (https=) |
| SG (1) | SG11202101273VA (https=) |
| WO (1) | WO2020037150A2 (https=) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019016989A2 (pt) | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| AU2018345303B2 (en) | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| PH12021552002A1 (en) | 2019-02-20 | 2022-09-19 | Denali Therapeutics Inc | Anti-trem2 antibodies and methods of use thereof |
| CA3165846A1 (en) | 2019-12-23 | 2021-07-01 | Denali Therapeutics Inc. | Progranulin variants |
| PE20221465A1 (es) | 2020-01-13 | 2022-09-21 | Denali Therapeutics Inc | Anticuerpos anti-trem2 y metodos para utilizarlos |
| PE20231931A1 (es) | 2020-10-14 | 2023-12-01 | Denali Therapeutics Inc | Proteinas de fusion que comprenden enzimas sulfoglucosamina sulfohidrolasa y metodos de estas |
| EP4392064A4 (en) * | 2021-08-25 | 2025-12-24 | Denali Therapeutics Inc | MODIFIED ANTI-HER2 BISPECIFIC PROTEINS |
| KR20240116743A (ko) * | 2021-11-09 | 2024-07-30 | 한양대학교 산학협력단 | Fc 변이체를 포함하는 이종이합체 및 이의 제조방법 |
| JP2025503437A (ja) * | 2021-12-17 | 2025-02-04 | デナリ セラピューティクス インコーポレイテッド | ポリペプチド操作、ライブラリー、ならびに操作されたｃｄ９８重鎖及びトランスフェリン受容体結合ポリペプチド |
| US12011489B2 (en) * | 2022-03-30 | 2024-06-18 | Christopher Key | Compositions and methods for treating inflammatory disease |
| JP2025525792A (ja) | 2022-07-29 | 2025-08-07 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | トランスフェリン受容体１に対して再標的化されるウイルス粒子 |
| CA3263494A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | ANTI-TFR FUSIONS: PAYLOAD AND THEIR METHODS OF USE |
| IL318625A (en) | 2022-07-29 | 2025-03-01 | Regeneron Pharma | Compositions and methods for transferrin receptor (TFR)-mediated delivery to brain and muscle |
| CN118221803A (zh) * | 2022-12-19 | 2024-06-21 | 深圳科兴药业有限公司 | 异源二聚体Fc融合蛋白及其用途 |
| AU2024317483A1 (en) | 2023-07-28 | 2026-01-29 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:gaa and anti-cd63:gaa insertion for treatment of pompe disease |
| US20250049896A1 (en) | 2023-07-28 | 2025-02-13 | Regeneron Pharmaceuticals, Inc. | Anti-tfr:acid sphingomyelinase for treatment of acid sphingomyelinase deficiency |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050249723A1 (en) * | 2003-12-22 | 2005-11-10 | Xencor, Inc. | Fc polypeptides with novel Fc ligand binding sites |
| US8367805B2 (en) * | 2004-11-12 | 2013-02-05 | Xencor, Inc. | Fc variants with altered binding to FcRn |
| JP6226752B2 (ja) * | 2012-02-09 | 2017-11-08 | 中外製薬株式会社 | 抗体のＦｃ領域改変体 |
| WO2014189973A2 (en) | 2013-05-20 | 2014-11-27 | Genentech, Inc. | Anti-transferrin receptor antibodies and methods of use |
| JP6744856B2 (ja) * | 2014-04-08 | 2020-08-19 | プロセナ・バイオサイエンシズ・リミテッド | α−シヌクレインを認識する抗体を含む血液脳関門シャトル |
| WO2016207091A1 (en) * | 2015-06-24 | 2016-12-29 | F. Hoffmann-La Roche Ag | Trispecific antibodies specific for her2 and a blood brain barrier receptor and methods of use |
| TWI769982B (zh) | 2015-06-24 | 2022-07-11 | 日商Ｊｃｒ製藥股份有限公司 | 通過血腦障壁之抗人類運鐵蛋白受體抗體 |
| MX391086B (es) * | 2015-06-24 | 2025-03-21 | Hoffmann La Roche | Anticuerpos anti-receptor de transferrina con afinidad diseñada. |
| JP6932700B2 (ja) * | 2015-09-15 | 2021-09-08 | アムジエン・インコーポレーテツド | ４価の二重特異性抗原結合タンパク質及び４価の四重特異性抗原結合タンパク質、ならびにそれらの使用 |
| US10457717B2 (en) * | 2017-02-17 | 2019-10-29 | Denali Therapeutics Inc. | Engineered polypeptides |
| BR112019017021A2 (pt) * | 2017-02-17 | 2020-04-14 | Denali Therapeutics Inc | anticorpos anti-tau e métodos de uso dos mesmos |
| BR112019016989A2 (pt) * | 2017-02-17 | 2020-05-26 | Denali Therapeutics Inc. | Polipeptídeos de ligação ao receptor de transferrina manipulados |
| WO2018237338A1 (en) * | 2017-06-23 | 2018-12-27 | Denali Therapeutics Inc. | Anti-alpha-synuclein antibodies and methods of use thereof |
| WO2019055841A1 (en) * | 2017-09-14 | 2019-03-21 | Denali Therapeutics Inc. | ANTI-TREM2 ANTIBODIES AND METHODS OF USE |
| AU2018345303B2 (en) * | 2017-10-02 | 2025-09-18 | Denali Therapeutics Inc. | Fusion proteins comprising enzyme replacement therapy enzymes |
| WO2019094608A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Anti-bace1 antibodies and methods of use thereof |
| WO2019094576A1 (en) * | 2017-11-08 | 2019-05-16 | Denali Therapeutics Inc. | Bace-tau bispecific antibodies |
| TW201934573A (zh) * | 2018-01-10 | 2019-09-01 | 美商戴納立製藥公司 | 轉鐵蛋白受體結合性多肽及其用途 |
| CA3101202A1 (en) * | 2018-06-18 | 2019-12-26 | Denali Therapeutics Inc. | Fusion proteins comprising progranulin |
-
2019
- 2019-08-15 MA MA053616A patent/MA53616A/fr unknown
- 2019-08-15 MX MX2021001711A patent/MX2021001711A/es unknown
- 2019-08-15 CN CN201980066244.0A patent/CN112839955A/zh active Pending
- 2019-08-15 KR KR1020217007602A patent/KR20210064199A/ko not_active Withdrawn
- 2019-08-15 SG SG11202101273VA patent/SG11202101273VA/en unknown
- 2019-08-15 AU AU2019320803A patent/AU2019320803A1/en not_active Abandoned
- 2019-08-15 WO PCT/US2019/046705 patent/WO2020037150A2/en not_active Ceased
- 2019-08-15 EA EA202190542A patent/EA202190542A1/ru unknown
- 2019-08-15 BR BR112021002730-0A patent/BR112021002730A2/pt not_active IP Right Cessation
- 2019-08-15 JP JP2021507761A patent/JP7397063B2/ja active Active
- 2019-08-15 EP EP19849330.6A patent/EP3850007A4/en not_active Withdrawn
- 2019-08-15 CA CA3109763A patent/CA3109763A1/en active Pending
-
2021
- 2021-02-11 US US17/174,231 patent/US20220017634A1/en not_active Abandoned
- 2021-02-15 IL IL280882A patent/IL280882A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021533779A5 (https=) | ||
| JP2021510162A5 (https=) | ||
| AU2015357053B2 (en) | Domain-exchanged antibody | |
| KR101522954B1 (ko) | 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도 | |
| JP2023085476A5 (https=) | ||
| JP2021534220A5 (https=) | ||
| JP2024150674A5 (https=) | ||
| JPWO2020037150A5 (https=) | ||
| IL269395B1 (en) | Immunoconjugations of anti–PD–1 antibody with IL–2 or IL–15 mutation | |
| JP2019533441A5 (https=) | ||
| JP2018537966A5 (https=) | ||
| JP2018504092A5 (https=) | ||
| JP2021521781A5 (https=) | ||
| JPWO2019140050A5 (https=) | ||
| JP2026035742A5 (https=) | ||
| JPWO2022102768A5 (https=) | ||
| JPWO2022094299A5 (https=) | ||
| JPWO2020041604A5 (https=) | ||
| JPWO2021064137A5 (https=) | ||
| US20250277055A1 (en) | Bi- or multi-specific antibody | |
| JPWO2019216436A1 (ja) | 抗体の抗原結合領域を含み、生理活性ペプチドを融合する人工タンパク質 | |
| JPWO2019204398A5 (https=) | ||
| JPWO2021052349A5 (https=) | ||
| JPWO2021168194A5 (https=) | ||
| JPWO2023028543A5 (https=) |